PYLCLARI® should be used in designated nuclear medicine facilities only and should only be handled by authorised personnel.

This medicinal product is for diagnostic use only

PYLCLARITM is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

This medicinal product is for diagnostic use only

PYLCLARI® is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:

Detailed recommendations for the use of this product can be found in the Summary of Product Characteristics (SmPC)

Looking for training on how to interpret piflufolastat (18F) images?

Refresh your knowledge on guidelines and test yourself with some clinical cases interpretations

Pre-register to our piflufolastat (18F) Image Interpretation Training now

Looking for training on how to interpret piflufolastat (18F) images?

Refresh your knowledge on guidelines and test yourself with some clinical cases interpretations

[situaciones_clinicas]

Podcast de expertos

[podcast_carrusel]
[podcast_movil]

El Chester de SEMES en VIH

[chester_destacado]
[el_chester_de_semes]

Contact

Error: Formulario de contacto no encontrado.

Pre-register to our piflufolastat (18F) Image Interpretation Training now

Important notice

The information on this page is intended for use by healthcare providers only. By continuing, you automatically confirm that you are a professional healthcare provider in a European country

Yes
No

Thank you!

You are now pre-registered for PYLCLARI™ training. We have received your details and are currently processing your request. Once this is completed, Curium will contact you with instructions on how to access the content.